An epidemiology-based model for the operational allocation of COVID-19 vaccines: A case study of Thailand

Jarumaneeroj, Pisit; Dusadeerungsikul, Puwadol Oak; Chotivanich, Tharin; Nopsopon, Tanawin; Pongpirul, Krit

doi:10.1016/j.cie.2022.108031

Cited by 19 publications

(14 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many mathematical models have been proposed to describe the dynamics of the COVID-19 pandemic under mass vaccination programs. We found that both deterministic [1] , [21] , [22] ; Tran Kiem et al [24] , [28] ,MacIntyre et al [31] ) and stochastic [23] , [35] models are addressed. These studies provided significant results and relevant contributions to public health management.…”

Section: Introductionmentioning

confidence: 90%

Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer

Siqueira

Duarte

Moura

2022

Vaccine

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 90%

Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer

Siqueira

Duarte

Moura

2022

Vaccine

View full text Add to dashboard Cite

“…Although its government opted out from accessing the COVAX facility, it received donated vaccines from other countries to augment its supply at the time. Following the public outcry, the government also enhanced its vaccine procurement, indicating that at least two brands of vaccines would be available at the end of 2021 [ 2 , 11 ].…”

Section: Obstacles For Herd Immunitymentioning

confidence: 99%

“…In addition to supply limitations at the time, the vaccine rollout was also hampered by the country's inefficient vaccine allocation model. An epicentre‐based strategy was used until recently when lockdowns were being implemented which allocated the vaccines where prevalence of COVID‐positive cases were detected [ 11 ]. The epidemiology of COVID‐19 was ignored, notably the aspects of demographic distribution and the dynamics of transmissibility itself.…”

Section: Obstacles For Herd Immunitymentioning

confidence: 99%

Can Thailand achieve COVID‐19 herd immunity?

Jitanan

Chirasatienpon

Tiamjan

et al. 2022

Public Health Challenges

View full text Add to dashboard Cite

The COVID‐19 outbreak has had a great impact on the social, economic, and health systems of Thailand. A variety of measures to curb the spread of the disease were implemented since the beginning of the pandemic, including a strict national lockdown protocol. The Thai government aimed to achieve herd immunity through an efficient vaccination programme. Initially, vaccine supply shortage and a lack of vaccine options plagued the health system, but this has since been improved. Continuous monitoring of the situation through research is being carried out to assess the level of immunity among the population whereby the current general recommendation is presently a fourth booster dose for adults. Hurdles towards achieving herd immunity remain. One such issue is the low level of vaccine literacy among those that are unvaccinated or inadequately vaccinated. Another obstacle is the sizeable rate of hesitancy towards getting booster doses. Achieving herd immunity in the Thai population would require multilateral cooperation, improved health promotion to target population groups, such as older adults, and a developed distribution system for those with limited access, such as those in the rural areas.

show abstract

“…Frontline healthcare workers (HCWs), people with underlying chronic conditions, and people aged ≥60 years were prioritized target populations for vaccination [ 5 ]. Given the high number of COVID-19 cases in Bangkok, the capital city of Thailand, it was classified as a red zone and considered a top priority for vaccination [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

The Effects of CoronaVac and ChAdOx1 nCoV-19 in Reducing Severe Illness in Thailand: A Retrospective Cohort Study

et al. 2023

View full text Add to dashboard Cite

Two primary vaccines for coronavirus disease 2019 (COVID-19) have been rolled out in the mass vaccination campaign that started simultaneously with the spread of the delta variant. To explore the vaccines’ effect on reducing viral load and disease severity, we conducted a retrospective cohort study in Thai patients aged ≥ 18 years who were confirmed COVID-19 positive by RT-PCR. Compared to unvaccinated patients, Ct values and the number of severe cases among vaccine regimens were analyzed. Ct values of vaccinated patients were not significantly different from unvaccinated patients, despite an increase of Ct values in a booster dose. The adjusted odd ratio for prevention of delta-related severe diseases was 0.47, 95% CI: 0.30–0.76 and 0.06, 95% CI: 0.01–0.45 after receiving one dose and two doses, respectively. No severe illness was found in booster-vaccinated individuals. Focusing on the vaccine types, one dose of ChAdOx1 nCoV-19 gave significant protection, whereas one dose of CoronaVac did not (0.49, 95% CI: 0.30–0.79, p = 0.003 vs. 0.28, 95% CI: 0.04–2.16, p = 0.223). Two-dose vaccination showed robust protective effects in all subpopulations regardless of vaccine type. Vaccinations with two primary vaccines could not reduce viral load in patients with COVID-19, but could prevent severe illness.

show abstract

An epidemiology-based model for the operational allocation of COVID-19 vaccines: A case study of Thailand

Cited by 19 publications

References 44 publications

Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer

Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer

Can Thailand achieve COVID‐19 herd immunity?

The Effects of CoronaVac and ChAdOx1 nCoV-19 in Reducing Severe Illness in Thailand: A Retrospective Cohort Study

Contact Info

Product

Resources

About